Single Blood Test Simultaneously Captures Immune, Stromal, and Tumor Signals Linked to Immunotherapy Response and Resistance in Sarcoma

by

CHICAGO — Aqtual, Inc., a precision medicine company developing active chromatin cell-free DNA (cfDNA) diagnostics for oncology and chronic disease, today announced new findings demonstrating its blood-based active chromatin cell-free DNA platform can simultaneously evaluate immune, stromal, and tumor-associated genomic biology from a single blood-based assay. These results highlight the potential of this approach to noninvasively monitoring dynamic changes in tumor microenvironment and emerging mechanisms of treatment resistance. The findings, led by investigators at UHN’s Princess Margaret Cancer Centre, were published in the peer-reviewed journal npj Precision Oncology [1] and will be extended with new longitudinal resistance analyses presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 – June 2 in Chicago. Read More